MGI PHARMA to Present at the Merrill Lynch Global Pharmaceutical Biotechnology and Medical Devices Conference

Business Wire, Sept 12, 2007

MINNEAPOLIS -- MGI PHARMA, INC. (Nasdaq:MOGN) today announced that Lonnie Moulder, President and Chief Executive Officer of MGI PHARMA, will present at the Merrill Lynch Global Pharmaceutical, Biotechnology and Medical Devices Conference in London, England on Thursday, September 20, 2007 at 8:00 a.m. ET. Mr. Moulder will provide an overview of the Company, its products, pipeline and 2007 corporate goals.

The presentation will be webcast live and may be accessed by logging on to MGI PHARMA's corporate website at www.mgipharma.com. Please connect to the Company's website at least 15 minutes prior to the live presentation to ensure adequate time for any software download that may be necessary to listen to the webcast. An archived version of the presentation will be available through September 27, 2007.

About MGI PHARMA

MGI PHARMA, INC. is a biopharmaceutical company focused in oncology and acute care that acquires, researches, develops and commercializes proprietary products that address the unmet needs of patients. MGI PHARMA has a portfolio of proprietary pharmaceuticals, and intends to become a leading biopharmaceutical company. MGI PHARMA markets Aloxi[R] (palonosetron hydrochloride) Injection, Dacogen[R] (decitabine) for Injection and Gliadel[R] Wafer (polifeprosan 20 with carmustine implant) in the United States. The Company directly markets its products in the U.S. and collaborates with partners to reach international markets.